Skip to main content

Mitsubishi Chemical and Fujitsu to Jointly Develop Genomics-based Drugs- Wall Street Journal

NEW YORK, March 5 – Mitsubishi Chemical has joined forces with Fujitsu, a large Japanese electronics and information technology company, to use genomics data to research and develop pharmaceuticals, the Wall Street Journal reported Monday.

The two firms said in a statement that they hoped to promote genomics-based drugs and personalized medicine to create a "new life science society.” While the alliance has no specific projects yet, a joint task force will hash out the details of the alliance and develop a research focus.

"We have agreed to cooperate in creating new businesses as well as boosting existing businesses by combining biotechnology and information technology, which represent the key to technological development in the 21st century," the firms said in a statement.

Mitsubishi Chemical, the largest producer of chemicals in Japan, has recently shifted its attention to bolstering its life science and biotechnology businesses. Most recently, Mitsubishi acquired the rights to sell HTS Biosystem’s bioanalysis system for protein detection in Japan.

Fujitsu is also working with Daiichi Pharmaceutical and Celestar Lexico-Sciences, a biotech start-up, to develop genomics-based drugs. 

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.